Silexion Therapeutics Corp (SLXN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 18 | 179 | 39 | 115 | 268 |
| TOTAL | $18 | $179 | $408 | $440 | $593 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 115,386 | 115,303 | 115,006 | 115,129 | 115,209 |
| TOTAL | $115,386 | $115,303 | $115,006 | $115,129 | $115,209 |
| Total Assets | $115,403 | $115,482 | $115,414 | $115,569 | $115,802 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 660 | 630 | 310 | 53 | 60 |
| Accrued Expenses | 12 | 128 | 39 | 19 | 24 |
| TOTAL | $672 | $758 | $349 | $72 | $84 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 115,208 | 115,065 | 115,160 | 115,350 | 115,347 |
| TOTAL | $115,208 | $115,065 | $115,160 | $115,350 | $115,347 |
| Total Liabilities | $115,880 | $115,823 | $115,509 | $115,422 | $115,431 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 110 | 110 | 110 | 110 | 110 |
| Retained earnings | -1,154 | -1,197 | -951 | -709 | -485 |
| TOTAL | $-477 | $-340 | $-95 | $147 | $371 |
| Total Liabilities And Equity | $115,403 | $115,482 | $115,414 | $115,569 | $115,802 |